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A two-year-old girl with congenital dyserythropoietic anemia (CDA) acutely developed fever, tachypnea, and increased oxygen
requirement. Chest X-ray revealed bilateral interstitial infiltrates and mild cardiomegaly. Blood cultures grew no infectious agents,
while pulmonary specimens grew cytomegalovirus (CMV). Treatment with intravenous ganciclovir was initiated but without
response. Final cytologic preparations of bronchoalveolar lavage (BAL) fluid revealed eosinophilic amorphous material consistent
with pulmonary alveolar proteinosis (PAP). CDA and PAP are extremely rare disorders in pediatrics. PAP should be considered in
patients with hematological disorders who present with acute interstitial pneumonia, after infectious causes are ruled out.
1. Introduction
Congenital dyserythropoietic anemia type II (CDA II), also
known as HEMPAS (hereditary erythroblastic multinucle-
arity with positive acid serum test), is a rare hematological
autosomal recessive disorder whereby individuals have bone
marrow biopsy findings indicating inappropriate red blood
cell lineage progression [1]. Pulmonary alveolar proteinosis
(PAP) is also a rare disorder in which lipoproteinaceous
material congregates within alveolar spaces, leading to a host
with impaired pulmonary immunity and susceptibility to
opportunistic infection [2]. Although historically reported in
patients with various hematological disorders [3–8], to our
knowledge, this is the first case report of PAP associated with
CDA.
2. Case Report
A 23-month-old girl presented to our facility with one
week of worsening fevers, productive cough, and increased
work of breathing. Over the previous 3 months, she was
treated for presumed upper respiratory tract infections with
inhaled beta-agonists, inhaled steroids, oral steroids, and
several diﬀerent oral antibiotics. Relevant medical history
was significant for prematurity and severe anemia neces-
sitating intrauterine blood transfusions, CDA diagnosed at
20 months by bone marrow biopsy and aspiration that
was morphologically consistent with type II, and surgical
placement of a Port-a-Cath for chronic blood transfusions.
Initial vital signs were temperature 37.9 degrees Celsius,
heart rate 156 bpm, respiratory rate 50/min with oxygen
saturation 83% on room air and 98% on 1 LPM oxygen
by nasal cannula, and blood pressure 115/61mmHg. She
appeared in mild distress with increased work of breathing.
She had moderate frontal bossing with open anterior fonta-
nelle. Heart examination was significant for a II/IV systolic
ejectionmurmur. Lung exam revealed diﬀuse rales bilaterally
but no wheezing. Abdomen was not distended. The liver
was palpated 4 cm below the costal margin, and the spleen
palpated to the level of the umbilicus. She had no clubbing,
cyanosis, or peripheral edema.
Chest radiograph showed diﬀuse ground glass alveolar
infiltrates which were chronic in nature when compared to a
chest X-ray from one year prior (Figure 1). Blood, urine, and
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Figure 1: PA radiograph on admission: well-inflated lungs with
diﬀuse bilateral coarse reticular opacities and left IJ port.
respiratory cultures were sent, and the patient was started
empirically on oral azithromycin and parenteral ceftriaxone.
On day 3, a transthoracic echocardiogram revealed
a patent foramen ovale but no cardiomyopathic process.
An abdominal ultrasound confirmed hepatosplenomegaly.
Repeat chest X-ray showed no changes, and chest CT was
oﬀered but the parents refused.
Despite 4 days of antibiotics, the patient continued to
spike intermittent fevers and was still on oxygen treatment,
and there still were no changes on chest radiograph. Bron-
choscopy was performed and was anatomically normal. The
bronchoalveolar lavage (BAL) fluid was cloudy in appearance
and revealed no evidence of aspiration or malignant cells.
Grocott’s methenamine silver (GMS) stain was negative for
Pneumocystis jirovecii. Ziehl-Neelsen stain was negative for
acid-fast bacilli (AFB). Fungal, bacterial, AFB, RSV, and
influenza cultures of BAL fluid revealed no growth. Diﬀeren-
tial of the WBCs indicated 68% macrophages, 12% PMNs,
and 10% lymphocytes. Light microscopic examination of
BAL fluid using Periodic acid-Schiﬀ (PAS) stain was positive
for abundant amorphous material within the pulmonary
macrophages and also in larger extracellular aggregates
suggesting pulmonary alveolar proteinosis (Figure 2). The
lipid-laden macrophage (LLM) index was 120 [9].
On day 5, the patient’s work of breathing improved,
lung sounds improved, and the supplemental oxygen was
decreased to 0.5 LPM by nasal cannula. Antibacterials were
discontinued. On day 7, BAL fluid was positive for cyto-
megalovirus (CMV) by indirect fluorescent antibody testing
and serum CMV IgG and IgM antibodies were detected by
immunoassay, while CMVDNA of the blood remained nega-
tive. Ophthalmologic examination revealed no signs of CMV
retinitis. The patient was started on parenteral ganciclovir.
On day 9, the patient was weaned oﬀ supplemental oxygen
to room air. She continued IV ganciclovir and was discharged
from the hospital.
After completion of two weeks of ganciclovir, the patient
presented to her hematologist’s oﬃce for scheduled followup
and blood transfusion. Chest X-ray was repeated and showed
minimal interval improvement in the diﬀuse coarse reticular
opacities noted on X-ray from her most recent hospitaliza-
tion. Again, the parents refused CT scan. The patient was
subsequently lost to followup. Several months later she was
admitted to a hospital in another state in respiratory failure.
Per report, she required intubation and BAL was performed,
which confirmed PAP.
3. Discussion
Our patient presented with concerns of imminent respira-
tory failure and diﬀuse interstitial infiltrates on chest X-ray.
With the source unidentified by noninvasive means, and with
continuing illness despite medical management, BAL was
performed for diagnostic purposes. Initial findings suggested
that CMV was the culprit in our patient with apparent
bilateral pneumonia. However, lavage fluid also had findings
consistent with PAP. Despite adequate treatment with ganci-
clovir, the patient continued to have concerning respiratory
findings and a chest X-ray that remained essentially the
same. Physicians should consider BAL as both a diagnostic
and therapeutic tool early in the course of a patient with
hematological pathology presenting with diﬀuse pulmonary
infiltrates with unknown etiology.
The congenital dyserythropoietic anemias are very rare
disorders that can be divided into three groups: CDA I–III.
The morphological aberrancies of CDA II, which include
binucleated and multinucleated RBC precursor cells with
membrane irregularities as seen on our patient’s diagnostic
bone marrow sample, are thought to be secondary to hypo-
glycosylation of erythrocyte membrane proteins [10–12].
Complications that have been reported include splenomega-
ly, gallstones, jaundice, and pulmonary failure [13].
PAP is a rare disorder involving deposition of lipopro-
teinaceous material in alveoli and results in a deficit of sur-
factant clearance by pulmonary macrophages [3]. There are
3 types: acquired, secondary, and congenital. Secondary PAP
is associated with hematological malignancies and is well-
established in the literature [14]. Superimposed infection
is known to complicate the course of secondary PAP, and
reports of CMV and PAP have been reported [15].
To our knowledge, however, there are no published
accounts of PAP associated with CDA and the incidence of
these two rare disorders occurring simultaneously is remark-
able and elucidating a possible mechanism is intriguing.
While the acquired form of PAP is associated with an autoim-
mune process directed at the granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF), resulting in suppression of
proper alveolar function, the congenital type is associated
with a rare mutation in the GM-CSF receptor [3, 16, 17].
Along those same lines, secondary PAP in association with
hematological disorders such as CDA II could result from
defective GM-CSF receptors on pulmonary macrophages
and/or in a disrupted signal transduction pathway after GM-
CSF and receptor interaction, which has been proposed else-
where [8]. It is possible, as well, that our patient had a func-
tional impairment of alveolar macrophages resulting from
the environmental disruption of normal robust monocyte
production caused by pathogenic erythrocyte production
inherent to CDA II. Glycosylation defects of the monocytes
themselves are less likely as it has been shown such errors are
limited to erythroblasts [12].
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Figure 2: Evidence of pulmonary alveolar proteinosis: papanicolaou stain of bronchoalveolar lavage (BAL) fluid at medium power (20x)
view showing large, amorphous, acellular aggregates with a pulmonary macrophage adjacent to an aggregate in a background of chronic
inflammatory cells (a). Periodic acid-Schiﬀ (PAS) histochemical stain of BAL fluid at high power (40x) highlights both the large extracellular
amorphous aggregates as well as material within pulmonary macrophages (b).
The success of whole-lung lavage to relieve symptoms
in secondary PAP has been documented thoroughly [2].
The sudden improvement of our patient after BAL supports
this, and the lack of improvement after adequate antiviral
therapy argues against CMV as the primary culprit. Experts
feel CMV, and other infectious agents isolated in patients
with secondary PAP and hematopoietic aberrancy are likely
opportunistic infections superimposed on a preexistent PAP
and compromised immune system [18]. The diagnosis of
PAP alone, or in combination with superimposed CMV
infection, should be entertained in any pediatric patient
with a known hematological condition and new respiratory
changes with a chest X-ray showing diﬀuse lung disease.
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